{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["addiction", "adiponectin", "adiponectin receptors", "cancer", "opium"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "32607004", "DateRevised": {"Year": "2022", "Month": "04", "Day": "15"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "06", "Day": "15"}], "Language": ["eng"], "ELocationID": ["10.2147/CPAA.S256289"], "Journal": {"ISSN": "1179-1438", "JournalIssue": {"Volume": "12", "PubDate": {"Year": "2020"}}, "Title": "Clinical pharmacology : advances and applications", "ISOAbbreviation": "Clin Pharmacol"}, "ArticleTitle": "Overexpression of Adiponectin Receptors in Opium Users with and without Cancer.", "Pagination": {"StartPage": "59", "EndPage": "65", "MedlinePgn": "59-65"}, "Abstract": {"AbstractText": ["Opium addiction is a serious public health concern in the Middle East countries causing various illnesses. Opium use is associated with an increased risk of several cancers; however, the underlying mechanisms are not yet fully elucidated. Altered levels of adiponectin and its related main receptors, Adiponectin receptor 1 and 2 (AdipoR1 and AdipoR2) have been associated with several malignancies. Opium users are at risk of various cancers. All together let us to the hypothesis that probable overexpression of AdipoRs in opium users might be linked to the occurrence of cancer in this population.", "One hundred opium users along with 100 healthy non-opium users were enrolled in the study. Opium users were followed up for 5 years (2014-2019) to evaluate the occurrence of malignancies. AdipoR1 and AdipoR2 expressions were measured using a flow cytometry method.", "Expression of AdipoR1 and AdipoR2 was significantly higher in opium users compared with the healthy control group (P=0.0001 and 0.0001, respectively). Eight opium users developed cancer during the follow-up period. Subjects abusing opium developed cancer by 8.6 folds comparing to non-opium users (P=0.034; OR=8.6; 95% CI (1.06-70.1)). Expression of these two receptors was significantly higher in opium users developing cancer compared with cancer-free opium (P=0.001).", "Considering the significant overexpression of AdipoR1 and AdipoR2 in opium users and in opium users who developed malignancies and the association between upregulation of these receptors in most cancers affecting opium users and assessment of AdipoRs may serve as an early detection tool of cancer in this population."], "CopyrightInformation": "\u00a9 2020 Firouzabadi et al."}, "AuthorList": [{"Identifier": ["0000-0002-9293-9845"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology & Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran."}, {"Identifier": [], "Affiliation": "Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran."}, {"Identifier": [], "Affiliation": "Non-Communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran."}], "LastName": "Firouzabadi", "ForeName": "Negar", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology & Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran."}], "LastName": "Haghnegahdar", "ForeName": "Maral", "Initials": "M"}, {"Identifier": ["0000-0001-5786-051X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran."}], "LastName": "Khalvati", "ForeName": "Bahman", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran."}], "LastName": "Dehshahri", "ForeName": "Ali", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Digestive Disease Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Bahramali", "ForeName": "Ehsan", "Initials": "E"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Clin Pharmacol", "NlmUniqueID": "101564865", "ISSNLinking": "1179-1438"}, "CoiStatement": "The authors of the manuscript have no conflicts of interest to declare."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Mej\u00eda D. The war on drugs under plan Colombia. Rethinking \u201cWar on Drugs\u201d Through US-Mexico Prism. 2012;19."}, {"Citation": "First MB, Gibbon M, Spitzer RL, Williams JB. User\u2019s Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders Research Version. New York: Biometrics Research Department, New York State Psychiatric Institute; 1996."}, {"Citation": "Chehrazi E, editor Epidemiology of addiction in Iran. Proc 25th Iranian Medical Congress; 1976."}, {"Citation": "Alemi A, Naraghi M. The iceberg of opium addiction an epidemiological survey of opium addiction in a rural community. Drug Alcohol Depend. 1978;3(2):107\u2013112. doi:10.1016/0376-8716(78)90023-6", "ArticleIdList": ["10.1016/0376-8716(78)90023-6", "631011"]}, {"Citation": "Mee-Lee D. ASAM (American Society of Addiction Medicine) Patient Placement Criteria for the Treatment of Substance-Related Disorders. American Society of Addiction Medicine; 1996."}, {"Citation": "Narenjiha H, Rafiey H, Jahani MR, Assari S, Moharamzad Y, Roshanpazooh M. Substance-dependent professional drivers in Iran: a descriptive study. Traffic Inj Prev. 2009;10(3):227\u2013230. doi:10.1080/15389580902849017", "ArticleIdList": ["10.1080/15389580902849017", "19452363"]}, {"Citation": "Barber A, Gottschlich R. Opioid agonists and antagonists: an evaluation of their peripheral actions in inflammation. Med Res Rev. 1992;12(5):525\u2013562. doi:10.1002/med.2610120505", "ArticleIdList": ["10.1002/med.2610120505", "1513187"]}, {"Citation": "Vuong C, Van Uum SH, O\u2019dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2009;31(1):98\u2013132.", "ArticleIdList": ["PMC2852206", "19903933"]}, {"Citation": "Frenk H. Pro-and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems. Brain Res Rev. 1983;6(2):197\u2013210. doi:10.1016/0165-0173(83)90039-5", "ArticleIdList": ["10.1016/0165-0173(83)90039-5", "6315187"]}, {"Citation": "Dhawan B, Cesselin F, Raghubir R, et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev. 1996;48(4):567\u2013592.", "ArticleIdList": ["8981566"]}, {"Citation": "La Cava A. Leptin in inflammation and autoimmunity. Cytokine. 2017;98:51\u201358. doi:10.1016/j.cyto.2016.10.011", "ArticleIdList": ["10.1016/j.cyto.2016.10.011", "PMC5453851", "27916613"]}, {"Citation": "Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548\u20132556. doi:10.1210/jc.2004-0395", "ArticleIdList": ["10.1210/jc.2004-0395", "15181022"]}, {"Citation": "Flier JS, Cook KS, Usher P, Spiegelman BM. Severely impaired adipsin expression in genetic and acquired obesity. Science. 1987;237:405\u2013409. doi:10.1126/science.3299706", "ArticleIdList": ["10.1126/science.3299706", "3299706"]}, {"Citation": "Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPoseMost abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221(2):286\u2013289. doi:10.1006/bbrc.1996.0587", "ArticleIdList": ["10.1006/bbrc.1996.0587", "8619847"]}, {"Citation": "Funahashi T, Nakamura T, Shimomura I, et al. 3. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Internal Med. 1999;38(2):202\u2013206. doi:10.2169/internalmedicine.38.202", "ArticleIdList": ["10.2169/internalmedicine.38.202", "10225688"]}, {"Citation": "Saito K, Tobe T, Minoshima S, et al. Organization of the gene for gelatin-binding protein (GBP28). Gene. 1999;229(1):67\u201373. doi:10.1016/S0378-1119(99)00041-4", "ArticleIdList": ["10.1016/S0378-1119(99)00041-4", "10095105"]}, {"Citation": "Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439\u2013451. doi:10.1210/er.2005-0005", "ArticleIdList": ["10.1210/er.2005-0005", "15897298"]}, {"Citation": "Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes. 2000;24(7):861. doi:10.1038/sj.ijo.0801244", "ArticleIdList": ["10.1038/sj.ijo.0801244", "10918532"]}, {"Citation": "Hug C, Wang J, Ahmad NS, Bogan JS, Tsao T-S, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A. 2004;101(28):10308\u201310313. doi:10.1073/pnas.0403382101", "ArticleIdList": ["10.1073/pnas.0403382101", "PMC478568", "15210937"]}, {"Citation": "Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab. 2003;88(3):993\u2013997. doi:10.1210/jc.2002-021209", "ArticleIdList": ["10.1210/jc.2002-021209", "12629074"]}, {"Citation": "Soliman PT, Wu D, Tortolero\u2010Luna G, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006;106(11):2376\u20132381.", "ArticleIdList": ["16639730"]}, {"Citation": "Petridou ET, Mitsiades N, Gialamas S, et al. Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies. Oncology. 2007;73(3\u20134):261\u2013269. doi:10.1159/000127424", "ArticleIdList": ["10.1159/000127424", "18424891"]}, {"Citation": "Hewer T, Rose E, Ghadirian P, et al. Ingested mutagens from opium and tobacco pyrolysis products and cancer of the oesophagus. Lancet. 1978;312(8088):494\u2013496. doi:10.1016/S0140-6736(78)92218-3", "ArticleIdList": ["10.1016/S0140-6736(78)92218-3", "79865"]}, {"Citation": "Moossavi S, Mohamadnejad M, Pourshams A, et al. Opium use and risk of pancreatic cancer: a prospective cohort study. Cancer Epidemiol Prev Biomarkers. 2018;27(3):268\u2013273. doi:10.1158/1055-9965.EPI-17-0592", "ArticleIdList": ["10.1158/1055-9965.EPI-17-0592", "PMC5835180", "29263189"]}, {"Citation": "Kamangar F, Shakeri R, Malekzadeh R, Islami F. Opium use: an emerging risk factor for cancer? Lancet Oncol. 2014;15(2):e69\u2013e77. doi:10.1016/S1470-2045(13)70550-3", "ArticleIdList": ["10.1016/S1470-2045(13)70550-3", "24480557"]}, {"Citation": "Mahmoodpoor A, Golzari SE. Epigenetics, opium, and cancer. Lancet Oncol. 2014;15(4):e153. doi:10.1016/S1470-2045(14)70077-4", "ArticleIdList": ["10.1016/S1470-2045(14)70077-4", "24694638"]}, {"Citation": "Alizadeh H, Naghibzadeh Tahami A, Khanjani N, et al. Opium use and head and neck cancers: a matched case-control study in Iran. Asian Pacific J Cancer Prev. 2020;21(3):783\u2013790. doi:10.31557/APJCP.2020.21.3.783", "ArticleIdList": ["10.31557/APJCP.2020.21.3.783", "PMC7437338", "32212808"]}, {"Citation": "Szczepaniak A, Fichna J, Zieli\u0144ska M. Opioids in cancer development, progression and metastasis: focus on colorectal cancer. Curr Treat Options Oncol. 2020;21(1):6. doi:10.1007/s11864-019-0699-1", "ArticleIdList": ["10.1007/s11864-019-0699-1", "PMC6976545", "31970561"]}, {"Citation": "Ishikawa M, Kitayama J, Yamauchi T, et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci. 2007;98(7):1120\u20131127. doi:10.1111/j.1349-7006.2007.00486.x", "ArticleIdList": ["10.1111/j.1349-7006.2007.00486.x", "17459059"]}, {"Citation": "Hiyoshi M, Tsuno NH, Otani K, et al. Adiponectin receptor 2 is negatively associated with lymph node metastasis of colorectal cancer. Oncol Lett. 2012;3(4):756\u2013760. doi:10.3892/ol.2012.583", "ArticleIdList": ["10.3892/ol.2012.583", "PMC3362449", "22740988"]}, {"Citation": "Dalamaga M, Migdalis I, Fargnoli JL, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case\u2013control study. Cancer Causes Control. 2009;20(5):625\u2013633. doi:10.1007/s10552-008-9273-z", "ArticleIdList": ["10.1007/s10552-008-9273-z", "PMC2720089", "19051043"]}, {"Citation": "Poustchi H, Eghtesad S, Kamangar F, et al. Prospective epidemiological research studies in Iran (the PERSIAN Cohort Study): rationale, objectives, and design. Am J Epidemiol. 2018;187(4):647\u2013655. doi:10.1093/aje/kwx314", "ArticleIdList": ["10.1093/aje/kwx314", "PMC6279089", "29145581"]}, {"Citation": "Yeo C, Saunders N, Locca D, et al. Ficoll-Paque\u2122 versus Lymphoprep\u2122: a comparative study of two density gradient media for therapeutic bone marrow mononuclear cell preparations. Regen Med. 2009;4(5):689\u2013696. doi:10.2217/rme.09.44", "ArticleIdList": ["10.2217/rme.09.44", "19761394"]}, {"Citation": "UNODC W. Opioid Overdose: Preventing and Reducing Opioid Overdose Mortality. Vienna: United Nations Office of Drugs and Crime, World Health Organization; 2013."}, {"Citation": "Afshari M, Janbabaei G, Bahrami MA, Moosazadeh M. Opium and bladder cancer: A systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer. PLoS One. 2017;12(6):e0178527. doi:10.1371/journal.pone.0178527", "ArticleIdList": ["10.1371/journal.pone.0178527", "PMC5460843", "28586371"]}, {"Citation": "Bakhshaee M, Raziee HR, Afshari R, Amali A, Roopoosh M, Lotfizadeh A. Opium addiction and risk of laryngeal and esophageal carcinoma. Iranian j Otorhinolaryngol. 2017;29(90):19.", "ArticleIdList": ["PMC5307300", "28229058"]}, {"Citation": "Shakeri R, Kamangar F, Mohamadnejad M, et al. Opium use, cigarette smoking, and alcohol consumption in relation to pancreatic cancer. Medicine. 2016;95:28. doi:10.1097/MD.0000000000003922", "ArticleIdList": ["10.1097/MD.0000000000003922", "PMC4956779", "27428185"]}, {"Citation": "Guan G, Zhang D, Zheng Y, et al. microRNA-423-3p promotes tumor progression via modulation of AdipoR2 in laryngeal carcinoma. Int J Clin Exp Pathol. 2014;7(9):5683\u20135691.", "ArticleIdList": ["PMC4203180", "25337209"]}, {"Citation": "Christodoulatos GS, Spyrou N, Kadillari J, Psallida S, Dalamaga M. The role of adipokines in breast cancer: current evidence and perspectives. Curr Obes Rep. 2019;8(4):413\u2013433. doi:10.1007/s13679-019-00364-y", "ArticleIdList": ["10.1007/s13679-019-00364-y", "31637624"]}, {"Citation": "Gelsomino L, Naimo GD, Catalano S, Mauro L, And\u00f2 S. The emerging role of adiponectin in female malignancies. Int J Mol Sci. 2019;20(9):2127. doi:10.3390/ijms20092127", "ArticleIdList": ["10.3390/ijms20092127", "PMC6539460", "31052147"]}, {"Citation": "Br\u00e5kenhielm E, Veitonm\u00e4ki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004;101(8):2476\u20132481. doi:10.1073/pnas.0308671100", "ArticleIdList": ["10.1073/pnas.0308671100", "PMC356975", "14983034"]}, {"Citation": "Sun G. Adiponectin-AdipoR1 axis in renal cell carcinoma plays a pivotal role in tumor progression and drug resistance. Am Soc Clin Oncol. 2019;37:634. doi:10.1200/JCO.2019.37.7_suppl.634", "ArticleIdList": ["10.1200/JCO.2019.37.7_suppl.634"]}, {"Citation": "Babi\u0144ska A, P\u0119ksa R, Wi\u015bniewski P, Sworczak K. Expression of adiponectin receptors 1 and 2 and the leptin receptor in human adrenal tumors. Arch Med Sci. 2019;15(5):1254. doi:10.5114/aoms.2018.76142", "ArticleIdList": ["10.5114/aoms.2018.76142", "PMC6764317", "31572471"]}, {"Citation": "Ramzan AA, Bitler BG, Hicks D, et al. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem. 2019;461(1\u20132):37\u201346. doi:10.1007/s11010-019-03586-9", "ArticleIdList": ["10.1007/s11010-019-03586-9", "PMC7490954", "31292831"]}, {"Citation": "Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007;25(12):1476. doi:10.1200/JCO.2006.07.2777", "ArticleIdList": ["10.1200/JCO.2006.07.2777", "17442990"]}, {"Citation": "MacLennan R, Da Costa J, Day N, Law CH, Ng Y, Shanmugaratnam K. Risk factors for lung cancer in Singapore Chinese, a population with high female incidence rates. Int J cancer. 1977;20(6):854\u2013860. doi:10.1002/ijc.2910200606", "ArticleIdList": ["10.1002/ijc.2910200606", "591126"]}, {"Citation": "Masjedi MR, Naghan PA, Taslimi S, et al. Opium could be considered an independent risk factor for lung cancer: a case-control study. Respiration. 2013;85(2):112\u2013118. doi:10.1159/000338559", "ArticleIdList": ["10.1159/000338559", "22759984"]}, {"Citation": "Khademi H, Malekzadeh R, Pourshams A, et al. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50 000 adults in Iran. BMJ. 2012;344:e2502. doi:10.1136/bmj.e2502", "ArticleIdList": ["10.1136/bmj.e2502", "PMC3328545", "22511302"]}, {"Citation": "Kubota N, Terauchi Y, Kubota T, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and-independent pathways. J Biol Chem. 2006;281(13):8748\u20138755. doi:10.1074/jbc.M505649200", "ArticleIdList": ["10.1074/jbc.M505649200", "16431926"]}, {"Citation": "Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to PPARgamma-agonists. J Biol Chem. 2005.", "ArticleIdList": ["16326714"]}, {"Citation": "Folkman J. Tumor angiogenesis In: Advances in Cancer Research. 43 Elsevier; 1985:175\u2013203.", "ArticleIdList": ["2581424"]}, {"Citation": "Howard J, Beddy P, Ennis D, Keogan M, Pidgeon G, Reynolds J. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. British J Surgery. 2010;97(7):1020\u20131027. doi:10.1002/bjs.7072", "ArticleIdList": ["10.1002/bjs.7072", "20632267"]}, {"Citation": "Denzel MS, Hebbard LW, Shostak G, Shapiro L, Cardiff RD, Ranscht B. Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clin Cancer Res. 2009;15(10):3256\u20133264. doi:10.1158/1078-0432.CCR-08-2661", "ArticleIdList": ["10.1158/1078-0432.CCR-08-2661", "PMC2905461", "19447866"]}, {"Citation": "Villa NY, Kupchak BR, Garitaonandia I, et al. Sphingolipids function as downstream effectors of a fungal PAQR receptor. Mol Pharmacol. 2008.", "ArticleIdList": ["PMC2684929", "19066337"]}, {"Citation": "Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011;17(1):55. doi:10.1038/nm.2277", "ArticleIdList": ["10.1038/nm.2277", "PMC3134999", "21186369"]}, {"Citation": "Takabe K, Paugh SW, Milstien S, Spiegel S. Inside-out\u201d signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60:181\u2013195. doi:10.1124/pr.107.07113", "ArticleIdList": ["10.1124/pr.107.07113", "PMC2695666", "18552276"]}, {"Citation": "Landskroner-Eiger S, Qian B, Muise ES, et al. Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res. 2009;15(10):3265\u20133276. doi:10.1158/1078-0432.CCR-08-2649", "ArticleIdList": ["10.1158/1078-0432.CCR-08-2649", "PMC3237387", "19447867"]}, {"Citation": "Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547\u2013594. doi:10.1210/er.2011-1015", "ArticleIdList": ["10.1210/er.2011-1015", "PMC3410224", "22547160"]}]}], "History": [{"Year": "2020", "Month": "4", "Day": "1"}, {"Year": "2020", "Month": "6", "Day": "5"}, {"Year": "2020", "Month": "7", "Day": "2", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "7", "Day": "2", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "7", "Day": "2", "Hour": "6", "Minute": "1"}, {"Year": "2020", "Month": "6", "Day": "15"}], "PublicationStatus": "epublish", "ArticleIdList": ["32607004", "PMC7304683", "10.2147/CPAA.S256289", "256289"]}}]}